汇宇制药：注射用HY0001a获受理

Core Viewpoint - The announcement indicates that Huiyu Pharmaceutical's wholly-owned subsidiary, Huiyu Haiyue, has received the acceptance notice from the National Medical Products Administration for the clinical trial application of injectable HY0001a for the treatment of advanced solid tumors, marking a significant milestone as it is the first drug targeting this specific site to enter clinical trials globally, with no similar products approved in the domestic or international markets [1] Group 1 - Huiyu Haiyue has received the acceptance notice for the clinical trial application of injectable HY0001a [1] - Injectable HY0001a is the first drug globally to disclose targeting this specific site for clinical trials [1] - There are currently no approved products targeting the same site in both domestic and international markets [1]